Bupivacaine + Epinephrine 0.5% | 5mg | 50mL Injectable MDV
Pfizer
-
RX License on File Required to Order
Detail
The Bupivacaine + Epinephrine 0.5% Injectable Solution (PFZ-00409175550) is a combination anesthetic designed to provide long-lasting local or regional anesthesia during a variety of medical, surgical, dental, and obstetric procedures. This multi-dose vial (MDV) contains 50mL of solution, with each mL delivering 5mg of bupivacaine hydrochloride combined with epinephrine at a ratio of 1:200,000. This dual-action formulation offers extended pain relief by blocking nerve signals and reducing blood flow in the treatment area, minimizing bleeding during surgery and prolonging the effect of the anesthetic.
Bupivacaine is a potent, long-acting local anesthetic that provides sustained pain control, making it ideal for procedures requiring prolonged anesthesia. The addition of epinephrine, a vasoconstrictor, helps extend the anesthetic's duration by slowing its absorption into the bloodstream, reducing systemic side effects, and controlling bleeding. This combination is especially useful in surgeries, dental work, and labor analgesia, where both effective pain management and reduced bleeding are critical.
Key Features:
- Prolonged Local Anesthesia: Bupivacaine provides long-lasting pain relief by inhibiting nerve signal transmission, ideal for procedures requiring extended anesthesia, such as surgeries or labor analgesia.
- Epinephrine for Vasoconstriction: The inclusion of epinephrine prolongs the duration of anesthesia by reducing blood flow, which helps to minimize bleeding and maintain a clear surgical field.
- 50mL Multi-Dose Vial (MDV): The multi-dose vial is designed for multiple administrations, offering convenience in clinical settings where repeated dosing may be necessary.
- 0.5% Concentration (5mg/mL): Each mL contains 5mg of bupivacaine, ensuring potent, long-acting anesthesia suitable for a variety of medical and surgical uses.
- Reduced Systemic Absorption: The vasoconstricting action of epinephrine minimizes the absorption of bupivacaine into the bloodstream, reducing the risk of systemic side effects such as hypotension or cardiac issues.